Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man, sup105
Search This Board:
Last Post: 9/1/2014 9:47:56 PM - Followers: 609 - Board type: Free - Posts Today: 13
 
MultiCell Technologies (MCET) 

 

 
Ticker - MCET (U.S. Reporting: SEC Filer) 

Shares Outstanding 3.90B
Float: 3.55B
% Held by Insiders 8.75%
% Held by Institutions 0.20%

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)
 


Partners

AmarinCorningPhizer



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  

Indication    

Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2    

Phase 3    

MCT-125

PMSF

X X X X  

MCT-465

Cancer

X        

MCT-475

Cancer

X        

MCT-485

Cancer

X X      


Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

MultiCell Technologies Inc. Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895
Office: (401) 762-0045
Email: info@multicelltech.com
Web: www.multicelltech.com

Find us on Google Maps  
    http://www.facebook.com/MCET.OB  
 


 Management and Board of Directors
 


Barbara (Corbett) Newmin - Investor Relations

Direct Phone: 401-762-0045
Direct Phone: 401-333-0610
Email: mcetinvestor@aol.com
Email: bcorbett@multicelltech.com
Email: info@multicelltech.com

 


W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Stephen Chang, PhD (Vice President, Research and Development)
Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller,  MBA/CFO
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.


Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.


Scientific Advisors

Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.


 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCET
Current Price
Volume:
Bid Ask Day's Range
Wiki
MCET News: MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer 08/25/2014 08:51:00 AM
MCET News: Confidential Treatment Order (ct Order) 08/21/2014 09:53:41 AM
MCET News: Quarterly Report (10-q) 07/15/2014 09:15:45 AM
MCET News: MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer 03/20/2014 08:39:00 AM
MCET News: MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer 03/20/2014 08:39:00 AM
PostSubject
#37723  Sticky Note Bloomberg Wire: MultiCell Technologies Granted U.S. Patent Covering Dip66 08/25/14 03:23:16 PM
#37196  Sticky Note Answer to all sup105 08/10/14 09:19:29 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#38166   I've seen hundreds of companies with many patents nutriman24 09/01/14 09:47:56 PM
#38165   Yes ..New Patents willbring in a partnership deal newlonginvest 09/01/14 05:23:10 PM
#38164   That is true! Let us wait and see eshety 09/01/14 03:57:14 PM
#38163   You wanna bet? Lol it's not gonna move Turtledip 09/01/14 03:28:15 PM
#38162   New Patents could Easily bring in a partnership Decarz 09/01/14 03:25:44 PM
#38161   If partnered with big pharma believe me it eshety 09/01/14 10:06:24 AM
#38160   Should be huge up week .. Huge patent newlonginvest 09/01/14 09:45:19 AM
#38159   We know the details of these "ties". simon wagstaff 09/01/14 09:02:54 AM
#38158   They already have ties with some of the HorseShoe Man 09/01/14 08:42:42 AM
#38157   "Expectation is so much that the company might simon wagstaff 09/01/14 07:35:15 AM
#38156   O . . Odessa you must write more often bontooth 09/01/14 02:32:14 AM
#38155   225 million damn only a fool would put Turtledip 09/01/14 01:51:40 AM
#38154   . . Which won't be held again for bontooth 09/01/14 01:45:24 AM
#38153   I feel this past PR was just the Dip66 08/31/14 11:31:55 PM
#38152   Whats 5% 4.5 billion lol Tambra3077 08/31/14 09:03:50 PM
#38151   Should be steady up now .huge bid . newlonginvest 08/31/14 07:44:16 PM
#38150   0007 sold at the first run then rebought Turtledip 08/31/14 07:37:22 PM
#38149   Criminal scum NITE, CSTI and ETRF have nearly tob999 08/31/14 07:01:15 PM
#38148   How many 5% or greater shareholders here? illionaire 08/31/14 01:02:53 PM
#38147   There's a difference between the truth and your opinions. illionaire 08/31/14 12:58:37 PM
#38146   What did you buy and sell at? How illionaire 08/31/14 12:56:31 PM
#38144   This will should be steady huge up newlonginvest 08/31/14 10:59:35 AM
#38143   "companies like MultiCell, which hold valuable disease related simon wagstaff 08/31/14 10:56:06 AM
#38142   Interesting Forbes article, with a point of view Odessa99 08/31/14 10:07:15 AM
#38141   You are right. ferenc 08/31/14 09:52:54 AM
#38140   Uptrend started and steady up from this week newlonginvest 08/31/14 08:21:02 AM
#38139   "It's not true... The can always can do simon wagstaff 08/31/14 07:49:23 AM
#38138   I belive those negatives have very good research gggamm338 08/31/14 07:23:42 AM
#38137   someone follow his and sold off at 6. gggamm338 08/31/14 05:33:43 AM
#38136   I been with MCET off and on since Turtledip 08/31/14 03:51:56 AM
#38135   Turtledip . . you know darn well that bontooth 08/31/14 03:48:11 AM
#38134   But I will buy gradually if I see Turtledip 08/31/14 03:43:28 AM
#38133   Oh I'm truly hurt it's not negative Turtledip 08/31/14 03:26:36 AM
#38132   You claim you bought, but why would you ckmseven788 08/31/14 03:25:01 AM
#38131   I can bet any of you here that Turtledip 08/31/14 03:24:09 AM
#38130   Nope I'm not at a loss. I rode Turtledip 08/31/14 03:22:13 AM
#38129   and, and, and, uhhh, umm,...get some more followers ckmseven788 08/31/14 03:21:58 AM
#38128   It ain't the sellers or buyers my friend, ckmseven788 08/31/14 03:18:46 AM
#38127   Nope not short I buy low sell high Turtledip 08/31/14 03:18:33 AM
#38126   Listen up I been long and invested in Turtledip 08/31/14 03:14:41 AM
#38125   Yeah, your name must be Johnny, or Mark ckmseven788 08/31/14 03:14:09 AM
#38124   DIS DOOD IS SHORT ckmseven788 08/31/14 03:11:40 AM
#38123   Anyone with a 5th grade education can understand ckmseven788 08/31/14 03:03:11 AM
#38122   . . ok bontooth 08/31/14 03:02:12 AM
#38121   So what's your point? What are you implying Turtledip 08/31/14 12:47:04 AM
#38120   A $3 billion offer was tendered in 2014 Odessa99 08/30/14 07:48:51 PM
#38119   Yes next week should Bou ce up newlonginvest 08/30/14 07:30:49 PM
#38118   It's not true... The can always can do ferenc 08/30/14 06:56:56 PM
#38117   I believe the MMs will lay off the ckmseven788 08/30/14 04:28:09 PM
#38116   Chase up will start next week newlonginvest 08/30/14 04:03:46 PM
PostSubject